Vaibhav Kumar

3PUBLICATIONS
21CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Jun 10, 2024
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer.

Sandra J Casak, Vaibhav Kumar, Chi Song

|Dec 09, 2022
FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor.

Vaibhav Kumar, Leslie Doros, Margaret Thompson

|Sep 24, 2020
D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer.

Vaibhav Kumar, Joseph R Shaw, Nigel S Key

Pageof 1